These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104 [TBL] [Abstract][Full Text] [Related]
29. New drug overview. Celecoxib. Am J Health Syst Pharm; 1999 May; 56(10):1031. PubMed ID: 10365731 [No Abstract] [Full Text] [Related]
30. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. Lee KK; You JH; Ho JT; Suen BY; Yung MY; Lau WH; Lee VW; Sung JY; Chan FK Aliment Pharmacol Ther; 2003 Jul; 18(2):217-22. PubMed ID: 12869082 [TBL] [Abstract][Full Text] [Related]
31. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. Cryer B; Luo X; Assaf AR; Sands G; Mardekian J Curr Med Res Opin; 2011 Feb; 27(2):295-302. PubMed ID: 21142617 [TBL] [Abstract][Full Text] [Related]
32. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. McKenna F; Arguelles L; Burke T; Lefkowith J; Geis GS Clin Exp Rheumatol; 2002; 20(1):35-43. PubMed ID: 11892706 [TBL] [Abstract][Full Text] [Related]
33. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity. Juni P; Sterchi R; Dieppe P BMJ; 2003 Feb; 326(7384):334; author reply 334. PubMed ID: 12574052 [No Abstract] [Full Text] [Related]
34. Celecoxib--a rational alternative to NSAIDs. Moodley I; Hirsch G S Afr Med J; 2001 Jan; 91(1):36-40. PubMed ID: 11236293 [No Abstract] [Full Text] [Related]
35. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy. Walan A; Wahlqvist P Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S79-88. PubMed ID: 10379474 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. Yen ZS; Lai MS; Wang CT; Chen LS; Chen SC; Chen WJ; Hou SM J Rheumatol; 2004 Sep; 31(9):1797-803. PubMed ID: 15338503 [TBL] [Abstract][Full Text] [Related]
37. [Pharma-clinics. The drug of the month. Celecoxib (Celebrex)]. Scheen AJ Rev Med Liege; 2001 Jan; 56(1):53-5. PubMed ID: 11256140 [TBL] [Abstract][Full Text] [Related]
38. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327 [TBL] [Abstract][Full Text] [Related]
39. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Clemett D; Goa KL Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043 [TBL] [Abstract][Full Text] [Related]